Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03207373
Other study ID # 2016-01943
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date April 13, 2017
Est. completion date January 30, 2024

Study information

Verified date January 2024
Source University Children's Hospital, Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with preexcitation are at risk for sudden cardiac death. The pathogenesis is a rapid antegrade conduction of atrial fibrillation over the accessory pathway to the ventricle resulting in ventricular fibrillation. Today it is possible to eliminate the conduction over the accessory pathway by catheter intervention (radiofrequency ablation) with a low rate of complications and a high rate of success. In clinical practice it is therefore important to estimate the risk for sudden cardiac death in an individual patient to give an advice to the patient and the parents about the further evaluation and therapeutic strategy. The velocity of the conduction over the accessory pathway can be estimated by analysing the ECG during sinus tachycardia. If the preexcitation disappears at a relatively low heart rate, the risk for sudden death is less than in patients with persisting preexcitation at the maximal heart rate. Compared to the gold standard i.e. measurement of the refractory period of the accessory pathway during invasive electrophysiological study (EPS), the measurements at the stress ECG have been reported to be a relatively poor indicator for an elevated risk which may be explained by a high intraindividual variability of this test. This study is designed to define the clinical relevance of the stress ECG in paediatric patients with preexcitation (compared to the invasive electrophysiological study). First Hypothesis: The results of the 3 stress ECG-tests are reproducible in an individual patient. Null hypothesis: there is no difference between the three measurements of cycle length during stress ECG. Alternate hypothesis: the difference between the three measurements of cycle length is > 10%. Second Hypothesis: There is a close correlation between the results at stress ECG and the results at the invasive electrophysiological Intervention.


Description:

Single centre, interventional study. There will be no randomisation or blinding. This study evaluates the stress ECG test as a non-invasive method of risk stratification in patients with WPW syndrome. For the non-invasive part a stress electrocardiogram on a treadmill is used. The invasive comparison is made with an electrophysiological study (EPS) in the catheterization laboratory. Nowadays the gold standard for measuring the antegrade effective refractory period of the accessory pathway is the invasive EPS. Study category A; there is only a minimal risk and a minimal burden to the study participants; The stress ECG test is a recommended test for this specific patient group as indicated in international guidelines. The responsible investigator at the single study site ensures that approval from an appropriately constituted Competent Ethics Committee (CEC), is sought for the clinical study. Objectives: 1) The study seeks primarily to evaluate the reproducibility of the loss of the preexcitation in repetitive stress ECG test in paediatric patients with WPW pattern in the view of an accurate estimation of the individual risk for sudden cardiac death. 2) To compare the results of non-invasive ECG measurements with measurements taken during invasive EPS and clinical/anatomical parameters. Planned Analysis: Descriptive statistic is applied to all clinical parameters. All the 3 cycle lengths out of the stress ECG are compared individually with the ERP-AP from the invasive EPS. If there is an average from the cycle length, this would be compared with the ERP-AP as well. And then we compare whether the difference between the cycle length and the ERP-AP is similar in a group of patients (high/low risk) or even in all patients. To demonstrate those results we use the Bland-Altman plot. There will also be a graph with the distribution of age of all patients. It will be interesting to see whether the age influences the results for example in relation to high or low risk. After the EPS, the patients are divided into 2 risk categories: high risk (ERP-AP ≤ 250 ms) and low risk (ERP-AP > 250ms) as measured at the EPS. At the end a risk factor analysis is made. All the parameters out of the case report form will be analysed whether the patient has high or low risk.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date January 30, 2024
Est. primary completion date January 30, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria: - Informed Consent as documented by signature (Appendix Informed Consent Form) - Preexcitation in resting ECG (WPW ECG Pattern) - Age between 8 and 18 years - Invasive EPS must be indicated/planned at the Children's Hospital Zurich Exclusion Criteria: - Inability to follow the procedures of the study, e.g. due to language problems or psychological disorders of the participant - Inability to walk/run on a treadmill

Study Design


Intervention

Diagnostic Test:
Stress test (ECG)
Every study participant undergoes a standard diagnostic stress ECG

Locations

Country Name City State
Switzerland University Childrens Hospital Zurich

Sponsors (1)

Lead Sponsor Collaborator
Christian Balmer

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Heart rate of 12-lead Resting ECG (bpm) 1 single measurement within 1 month
Other Rhythm during 12-lead Resting ECG sinus rhythm yes/no 1 single measurement within 1 month
Other axis of the QRS complex out of the 12-lead Resting ECG (degree) 1 single measurement within 1 month
Other Duration of PQ Interval out of the 12-lead Resting ECG (ms) 1 single measurement within 1 month
Other Duration of the QRS complex (ms) out of the 12-lead Resting ECG (ms) 1 single measurement within 1 month
Other Z-value of left ventricle (LV) out of Echocardiography Z-value LV 1 single measurement at aprox 1 month
Other Z-value of right ventricle (RV) out of Echocardiography Z-value RV 1 single measurement within 1 month
Other Z-value of left Atrium (LA) out of Echocardiography Z-value LA 1 single measurement within 1 month
Other Shortening fraction (SF) measured in Echocardiography SF (%) 1 single measurement within 1 month
Other Ejection fraction (EF) measured in Echocardiography 5 EF (%) 1 single measurement within 1 month
Other Valvular insufficiency measured in Echocardiography aorta-, pulmonal-, tricuspidal-, mitral insufficiency (no, minimal, moderate, severe) 1 single measurement within 1 month
Primary Cycle length (CL) at the Stress ECG Test Cycle length (ms) at the point when the delta wave disappears and/or at the point of maximal heart rate (HR) (ms) 3 test within a month
Secondary ERP-AP from invasive EPS Effective Refractory Period of Accessory Pathways (ERP-AP) during programmed atrial pacing (ms) 1 single measurement at aprox 1 month
Secondary SPERRI from invasive EPS Shortest pre excited Interval between two cardiac cycles (SPERRI) 1 single measurement at aprox 1 month
Secondary Anatomical localisation of the AP measured in the EPS leftsided (superior, posterosuperior, posterior, posteroinferior, inferior) or rightsided (paraseptal, inferior, anteroinferior, anterior, anterosuperior and superior) 1 single measurement at aprox 1 month
See also
  Status Clinical Trial Phase
Completed NCT02923726 - Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP N/A
Recruiting NCT05175937 - REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
Completed NCT02026102 - A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs) N/A
Completed NCT01262508 - Development of Algorithms to Predict Hemodynamic Instability N/A
Completed NCT00998218 - Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction Phase 3
Completed NCT00845286 - Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial N/A
Active, not recruiting NCT00562757 - Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias N/A
Completed NCT00622453 - Arrhythmias in Myotonic Muscular Dystrophy N/A
Completed NCT03833843 - Sudden Cardiac Death in Systemic Right Ventricle
Completed NCT04024865 - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Recruiting NCT05799833 - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting NCT05694572 - Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
Not yet recruiting NCT03622307 - Subcutaneous ICD Therapy Combined With VT Ablation for the Secondary Prevention of Sudden Cardiac Death N/A
Recruiting NCT02058771 - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Recruiting NCT02056509 - The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation. N/A
Terminated NCT01948206 - Study of Paced QRS Duration as a Marker of Sudden Cardiac Death N/A
Completed NCT01227785 - Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study N/A
Terminated NCT00524862 - Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death N/A
Completed NCT00534300 - Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker Phase 1/Phase 2
Recruiting NCT00181233 - Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk